Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries

Vaccine

Volumn 24, Issue SUPPL. 3, 2006, Pages

  Batson, Amie ^a   Meheus, Filip ^b   Brooke, Steve ^c  

^a WORLD BANK   (United States)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c PATH   (United States)

Author keywords

Advanced market commitments; HPV vaccine; Innovative financing mechanisms

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HUMAN; IMMUNIZATION; INVESTMENT; MEDICAL RESEARCH; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SCALE UP; SOCIOECONOMICS; VIRUS INFECTION; WART VIRUS; ECONOMICS; FEMALE; METHODOLOGY; REVIEW; UTERINE CERVIX TUMOR;

DEVELOPING COUNTRIES; FEMALE; FINANCING, ORGANIZED; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 33747891898     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.042     Document Type: Article

References (21)

1. WHO. Report of the consultation on human papillomavirus vaccines (2005), World health Organization, Geneva. http://www.who.int/vaccines-documents/
2. Mercer Management Consulting. Lessons learned: new procurement strategies for vaccines. Final report to the GAVI Board. 2002, http://www.gaviftf.org/docs_activities/pdf/lessons_learned_draft_final.pdf.
3. Glass S., Batson A., and Levine R. Issues paper: accelerating new vaccines (2001), Global Alliance for Vaccines and Immunization, Financing Task Force, Geneva. http://www.vaccinealliance.org/resources/18IssuesPaper.pdf
4. Miller M.A., and Flanders M.D. A model to estimate the probability of hepatitis B and Haemophilus influenzae type b vaccine uptake into national vaccination programs. Vaccine 18 (2000) 2223-2230
5. Children's Vaccine Initiative. CVI forum-special delivery vaccine industry issue, no. 11. 1996. p. 10.
6. World Bank Development Data. http://devdata.worldbank.org/hnpstats/query/default.html.
7. Batson A. The problems and promise of vaccine markets in developing countries. Health Affairs 24 (2005) 690-693
8. European Vaccine Manufacturers. Worldwide major vaccine manufacturers in figures (2004), European Vaccine Manufacturers, Brussels. http://www.evm-vaccines.org/pdfs/mfrs_in_figures.pdf
9. Batson A., Glass S., and Whitehead P. Vaccine economics: from candidates to commercialized products in the developing world. In: Levine M.M., Kaper J.B., Rappuoli R., et al. (Eds). New generation vaccines. 3rd ed. (2004), Marcel Dekker, New York 57-73 [revised and expanded]
10. Tsu V.D., and Pollack A.E. Preventing cervical cancer in low-resource settings: how far have we come and what does the future hold?. Int J Gynaecol Obstet 89 (2005) S55-S59
11. Batson A., Glass S., and Seiguer E. Economics of vaccines: from vaccine candidate to commercialized product. In: Bloom B.R., and Lambert P.-H. (Eds). The vaccine book (2003), Elsevier Press, San Diego, CA 345-370
12. Kettler H., and Towse A. Public-private partnerships for research and development: medicines and vaccines for diseases of poverty (2002), Office of Health Economics, London
13. Daems R., Del Giudice G., and Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 23 (2005) 5732-5742
14. Widdus R. Public-private partnerships for health require thoughtful evaluation. Bull World Health Organ 81 (2003) 235
15. Jacobs L., Godal T., and Martin J.-F. A paradigm for international cooperation: the Global Alliance for Vaccines and Immunization (GAVI) and the Vaccine Fund. In: Levine M.M., Kaper J.B., Rappuoli R., et al. (Eds). New generation vaccines. 3rd ed. (2004), Marcel Dekker, New York 101-115 [revised and expanded]
16. Brugha R., Starling M., and Walt G. GAVI, the first steps-lessons for the global fund. Lancet 359 (2002) 435-438
17. Ahun M. GAVI Phase 2 and IFFIm. Proceedings of the 13th WHO-AFRO task force on immunization (2006)
18. Boston Consulting, Group. Global vaccine supply: the changing role of suppliers (2005), BCG, Boston
19. WHO-UNICEF. Making a comprehensive multi-year plan (cMYP). Revised version 2.0. 2005, http://www.who.int/immunization_financing/tools/cmypguidelines.pdf.
20. Levine R., Kremer M., and Albright A. Making markets for vaccines: ideas to action (2005), Centre for Global Development, Washington, DC
21. Tremonti G. Advanced market commitments for vaccines: a new tool in the fight against disease and poverty. Report to the G8 Finance Ministers, London. 2005, http://www.dfid.gov.uk/consultations/amc-report-tremonti.pdf.